varilrix 10e3.3 ufp/0.5 ml pó e solvente para solução injetável
smithkline & french portuguesa - produtos farmacêuticos, lda. - vacina viva contra a varicela - pó e solvente para solução injetável - 10e3.3 ufp/0.5 ml - vírus da varicela-zoster vivo vírus da varicela-zoster vivo - varicella, live attenuated - vacina - duração do tratamento: curta ou média duração
varivax 1350 ufp/0.5 ml pó e veículo para suspensão injetável
merck sharp & dohme, lda. - vacina viva contra a varicela - pó e veículo para suspensão injetável - 1350 ufp/0.5 ml - vírus da varicela-zoster vivo 1350 u - varicella, live attenuated - vacina - duração do tratamento: curta ou média duração
spikevax (previously covid-19 vaccine moderna)
moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vacinas - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.
bcg vacina ajv 0.75 mg/1 ml pó e veículo para suspensão injetável
aj vaccines a/s - vacina contra a tuberculose (bcg) - pó e veículo para suspensão injetável - 0.75 mg/1 ml - mycobacterium tubercullosis typeus bovis, antigénio 0.75 mg/ml - tuberculosis, live attenuated - vacina - duração do tratamento: curta ou média duração
glivec
novartis biociencias s.a - mesilato de imatinibe - antineoplasico
ad live-suivax
fatro - vacina contra o vírus da doença de aujeszky - liofilizado e solvente para suspensão injetável - vírus da doença de aujeszky - suínos
bovilis intranasal rsp live
msd animal health, lda. - vacina contra o vírus da parainfluenza bovino e brsv (vírus respiratório sincicial bovino) - liofilizado e solvente para suspensão - bovinos
ervebo
merck sharp & dohme b.v. - recombinante vírus da estomatite vesicular (strain indiana), com exclusão do envelope glicoprotéico, substituído com o zaire ebolavirus (strain kikwit 1995), a glicoproteína de superfície - febre hemorrágica Ébola - vacinas - ervebo is indicated for active immunization of individuals 1 year of age or older to protect against ebola virus disease (evd) caused by zaire ebola virus. o uso de ervebo deve estar em conformidade com as recomendações oficiais.
mhyosphere pcv id
laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - porcos - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.
livetan 500 mg comprimido revestido por película
dr. willmar schwabe gmbh & co. - valeriana (raíz) - comprimido revestido por película - 500 mg - valeriana (raíz) 500 mg - valerianae radix - n/a - duração do tratamento: curta ou média duração